Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cretostimogene Grenadenorepvec vs Observation in IR-NMIBC
NCT06111235Phase 3Active, not recruiting
- Sponsor
- CG Oncology, Inc.
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing Cretostimogene after TURBT with Observation after TURBT (2 arms). Primary endpoint: Recurrence Free Survival at 29 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06111235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111235.